Please login to the form below

Not currently logged in


This page shows the latest rivaroxaban news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma

It was rejected by the CHMP a year ago. Ondexxya is intended for use in patients taking Pfizer/Bristol-Myers Squibb's Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) as

Latest news

More from news
Approximately 9 fully matching, plus 94 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Rivaroxaban. Rivaroxaban (Xarelto; Bayer and Johnson &Johnson) is an oral, once-daily, selective factor Xa inhibitor that is approved in the EU and US for the prevention of stroke and systemic ... In addition, rivaroxaban significantly reduced

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...